European CHMP recommends approval of roxadustat (Evrenzo) for the treatment of anaemia symptoms in patients with chronic kidney disease
Roxadustat is a first-in-class inhibitor of HIF prolyl hydroxylase that activates a response that occurs naturally when blood oxygen levels are low. Its effects on haemoglobin levels and need for rescue therapy are comparable to those seen with erythropoiesis-stimulating agents.
Source:
European Medicines Agency